Enliven Therapeutics raises $90M in PIPE, extends cash runway into late 2026

Enliven Therapeutics, Inc.

Gross proceeds ~$90M from sale of 5.36M shares at $14.00 and pre-funded warrants at $13.999.
PIPE priced at ~11% premium to March 18 close; expected to close March 21, 2024.
Proceeds plus existing cash expected to fund operations into late 2026 and through key clinical milestones.
ELVN-001 Phase 1a proof-of-concept data to be presented at KOL event on April 11, 2024.
ELVN-002 combination trial first patient dosing expected in Q2 2024; Phase 1 data in 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Enliven Therapeutics, Inc. entered into Purchase Agreement with the purchasers named therein valued at approximately $90 million (effective 2024-03-19).

Action: entry
Agreement: equity purchase
Counterparty: the purchasers named therein
Value: approximately $90 million
Effective: 2024-03-19

Exact text from the filing

On March 19, 2024, Enliven Therapeutics, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of (i) 5,357,144 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at $14.00 per Share, and (ii) pre-funded warrants (the “Pre-Funded Warrants") to purchase 1,071,505 shares of Common Stock

View on SEC.gov

284 material agreements filed in the last 30 days. Browse all material agreements →

Enliven Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-070839

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.